Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …

Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …

The discovery of epidermal growth-factor receptor (EGFR)-activating mutations and the
introduction of oral EGFR tyrosine kinase inhibitors (EGFR-TKIs) have expanded the …

Objectives Afatinib, an oral irreversible ErbB family blocker, has demonstrated efficacy in
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced lung …

Background Afatinib has demonstrated clinical benefit in patients with non-small-cell lung
cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively …

ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …

Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …

7525^ Background: Despite initial responses to reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …